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Abstract: Inherited arrhythmias and conduction system diseases are known causes of sudden cardiac death and are re-
sponsible for significant mortality and morbidity in patients with congenital heart disease and electrical disorders. Knowl-
edge derived from human genetics and studies in animal models have led to the discovery of multiple molecular defects 
responsible for arrhythmogenesis. This review summarizes the molecular basis of inherited arrhythmias in structurally 
normal and altered hearts. 
On the cellular and molecular levels, minor disturbances can provoke severe arrhythmias. Ion channels are responsible for 
the initiation and propagation of the action potential within the cardiomyocyte. Structural heart diseases, such as hypertro-
phic or dilated cardiomyopathies, increase the likelihood of cardiac electrical abnormalities. Ion channels can also be up- 
or down-regulated in congenital heart disease, altering action potential cellular properties and therefore triggering ar-
rhythmias. Conduction velocities may be inhomogeneously altered if connexin function, density or distribution changes.  
Another important group of electrophysiologic diseases is the heterogeneous category of inherited arrhythmias in the 
structurally normal heart, with a propensity to sudden cardiac death. There have been many recent relevant discoveries 
that help explain the molecular and functional mechanisms of long QT syndrome, Brugada syndrome, catecholaminergic 
polymorphic ventricular tachycardia, and other electrical myopathies. Identification of molecular pathways allows the 
identification of new therapeutic targets, for both disease palliation and cure. As more disease-causing mutations are iden-
tified and genotypic-phenotypic correlation is defined, families can be screened prior to symptom-onset and patients may 
potentially be treated in a genotype-specific manner, opening the doors of cardiac electrophysiology to the emerging field 
of pharmacogenomics.  
Received on: March 17, 2008 - Revised on: March 24, 2008 - Accepted on: March 24, 2008 
INTRODUCTION 
  Inherited arrhythmias can be life threatening, and are 
major cause of mortality and morbidity in developed nations. 
Identification of molecular pathways that increase suscepti-
bility to arrhythmia is necessary to prevent disease occur-
rence, to improve current therapies and to target new drug 
development. In recent years, the discovery of pathogenic 
mutations in inherited arrhythmia syndromes has provided 
novel insights for the understanding and treatment of dis-
eases predisposing to sudden cardiac death. In patients with 
the long QT syndromes (LQTS), genotype-phenotype rela-
tion studies [1] and genetic testing have influenced patient 
risk stratification [2] and refined treatment strategies [3]. 
  Arrhythmia mechanisms include abnormal automaticity, 
triggered activity, and re-entrant excitation. Each of these 
mechanisms can occur in any type of myocardial disease or 
in inherited cardiac arrhythmias. The current article focuses 
on molecular mechanisms of arrhythmias in the structurally 
abnormal and normal heart. Hypertrophic and dilated car-
diomyopathies, as well as arrhythmogenic right ventricular 
dysplasia/cardiomyopathy are common substrates of inher-
ited arrhythmias in the structurally abnormal heart. Genetic  
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diseases causing arrhythmias in the structural normal heart, 
also called electrical myopathies, include the long QT syn-
dromes, Brugada syndrome, catecholaminergic polymorphic 
ventricular tachycardia (CPVT), and non-defined familiar 
idiopathic ventricular fibrillation. Most, but not all of these 
disorders are caused by mutations in genes encoding cardiac 
ion-channel proteins. Among family members carrying an 
identical mutation in a single gene, remarkable phenotypic 
variability and expressivity may be observed, suggesting 
both environmental [4] and genetic modifiers [5].  
BACKGROUND 
 Fig.  (1A) summarizes the action potential in a non-
pacemaker cardiomyocyte and the contribution of distinct 
ion channels to the action potential shape. Voltage-gated Na
+ 
channels are essential for the amplitude and upstroke veloc-
ity of the cardiac action potential, which are important de-
terminants for impulse propagation and conduction velocity 
throughout the fast conducting conduction system and the 
working myocardium [6]. Potassium (K
+) channels control 
resting potentials, action potential waveforms, automaticity, 
and refractory periods [7]. Calcium (Ca
2+) channels contrib-
ute to the plateau phase of the action potential. In the past 
decade, numerous genes encoding various ion channels have 
been cloned and their structural biophysical properties, 
subunit stoichiometry, channel assembly and modulation by  
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intracellular second messengers and ligands have been 
characterized [8] (see Fig. 2).  
  There are three different mechanisms that lead to tach-
yarrhythmias: Increased automaticity of myocytes, triggered 
activity arising from early and delayed afterdepolarizations, 
and re-entry (see Fig. 3). Increased automaticity and trig-
gered activity are the typical mechanisms of non-re-entrant 
tachycardias [9]. 
  Increased automaticity of a myocyte denotes that the 
myocyte is able to depolarize itself, without an external 
stimulus. Normally, there is a stable resting membrane po-
tential in a cardiomyocyte. Only pacemaker cardiomyocytes 
depolarize in the absence of extrinsic stimulation. Those 
automatic cells spontaneously depolarize during phase 4 of 
the cardiac action potential, reach threshold, and initiate an 
action potential. 
  In contrary to increased automaticity where focal activity 
starts spontaneously, “triggered” rhythms typically require a 
preceding action potential. Thus, triggered activity means 
that arrhythmias originate from afterdepolarizations. An af-
terdepolarization is a premature depolarization of the mem-
brane potential before the ongoing action potential has 
reached the next phase 0. Afterdepolarizations arise as a con-
sequence of intracellular calcium oscillations. 
  Early afterdepolarizations occur during phase 2 or 3 (re-
polarization phase), whereas delayed afterdepolarizations 
occur during phase 4 (resting phase) (see Fig. 1). If an after-
depolarization is large enough, it can engage rapid sodium 
influx and thus initiate a premature action potential, which is 
clinically observed as a premature contraction. 
  Another common arrhythmia mechanism is re-entrant 
excitation. Re-entry contributes to the development of ven-
tricular tachycardia, a rapid, organized process in which the 
excitation travels a relatively well-defined circuit. Micro-re-
entrant circuits involve small regions of heart tissue such as 
seen in LQT and Brugada syndrome. Here, intramural reen-
try is caused by a transmural dispersion of refractoriness. 
Macro-re-entry involves large regions of heart tissue and is 
most commonly seen in hypertrophied or stretched myocar-
dium as seen in cardiomyopathies or in congenital heart dis-
ease (see Fig. 3).  
  Re-entry can degenerate to atrial or ventricular fibrilla-
tion, a chaotic electrical activity resulting from random 
propagation of multiple independent wavelets through the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Action potential in non-pacemaker cardiomyocytes. 
A). The action potential of atrial and ventricular myocytes consists of 4 phases (upper part), to which specific ion flows contribute (middle). 
The long plateau phase (3) and a stable resting phase (4) are characteristic for myocyte action potential. The corresponding electrocardio-
graphic ventricular activity is shown below. Early afterdepolarizations occur during phase 2 / 3 of the action potential, before the ongoing 
action potential has reached phase 0 (B). Delayed afterdepolarizations occur during phase 4 of the action potential, before the action potential 
has reached phase 0 (C). 162    Current Genomics, 2008, Vol. 9, No. 3  Wolf and Berul 
muscle. Fibrillation results in unorganized impulse propaga-
tion and absent contraction. 
ARRHYTHMIA MECHANISMS IN THE STRUC-
TURALLY ALTERED HEART 
Hypertrophic and Dilated Cardiomyopathies 
  Both hypertrophic cardiomyopathies (HCM) and dilated 
cardiomyopathies (DCM) are inherited disorders with a high 
incidence of lethal arrhythmias occurring at a young age. In 
both HCM and DCM, arrhythmias may occur unrelated to 
ischemia or heart failure.  
  HCM is a disease of the sarcomere and is the most com-
mon inherited cardiovascular disorder with a prevalence of 
0.2-0.5% in the general population [10-12]. Sudden death, at 
least partially due to malignant arrhythmias, accounts for at 
least 50% of deaths among patients with HCM [13]. 
  The actual mechanisms linking contractile dysfunction 
and arrhythmias remain poorly understood [14]. Multifacto-
rial biological substrates including genetic, functional, envi-
ronmental and hemodynamic features contribute to a high 
incidence of lethal ventricular tachycardias in cardiomy-
opathies. Histopathologic changes, such as myocardial fibro-
sis or myocyte disorganization and hypertrophy, might at-
tribute to re-entry and thus engender arrhythmia susceptibil-
ity [15, 16]. However, only ventricular hypertrophy and not 
histopathologic changes, correlated with increased arrhyth-
mia susceptibility in a HCM mouse model [17]. Increased 
automaticity by upregulation of pacemaker ion channel 
genes, which has been shown to occur in cardiac hypertro-
phy [18], could be another arrhythmia mechanism in HCM. 
Furthermore, sarcomere gene mutations alter cytosolic car-
diomyocyte Ca
2+ homeostasis [19] which promotes afterde-
polarizations triggering arrhythmias [20] (see Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Cellular substrates for action potential initiation and propagation. 
Displayed are transverse tubules of two neighboring cardiomyocytes with the ion channels localized on the sarcolemma of cell 1 and the 
connecting gap junction connexins to the sarcolemma of cell 2. Shown are the pore regions of the ion channels (-subunits) through which 
ions flow across the plasma membrane, and the cytoplasmic ß-subunits. Within each subunit, the encoding gene is displayed in italics, the 
protein in normal font. Differences in disease status are indicated in a box next to the currents. Intranuclear proteins and genes might also 
interact with ion channels and/or gap junction proteins. Disturbed calcium handling within the sarcomere or sarcoplasmic reticulum underlies 
distinct arrhythmia causing diseases. Molecular Mechanisms of Inherited Arrhythmias  Current Genomics, 2008, Vol. 9, No. 3    163 
  DCM is characterized by an increase in size of the ven-
tricular chambers and frequently is associated with arrhyth-
mias. Numerous mutations affecting the sarcomere and the 
cytoskeleton have been identified in DCM [21, 22]. The eti-
ology of arrhythmias occurring in DCM is poorly under-
stood, but it is known that stretch of the myocardium per se 
influences the shape and amplitude of the intracellular Ca
2+ 
transient, therefore favoring afterdepolarizations [23]. 
  DCM caused by mutations in the LMNA gene encoding 
for the inner nuclear membrane protein lamin A/C is associ-
ated with a high risk for arrhythmias and sudden death [24-
26] and sometimes involves progressive atrioventricular 
nodal disease [26-28]. Both arrhythmias and conduction sys-
tem disease can precede cardiac dilatation and presumably 
are a direct consequence of intrinsic changes of the myocyte 
secondary to lamin A/C deficiency [29].  
Arrhythmogenic Right Ventricular Dysplasia/Cardio- 
myopathy (ARVD/C) 
  ARVD/C refers to a genetically heterogeneous group of 
cardiomyopathies characterized by progressive degeneration 
and fibrofatty infiltration of the right ventricular myocar-
dium [30]. Patients are prone to ventricular tachycardia, right 
heart failure, and sudden death [31, 32]. Mutations in genes 
encoding for the desmosomal proteins plakoglobin [33], 
desmoplakin [34, 35], and plakophilin-2 [36] have been 
shown to cause ARVD/C. The molecular mechanisms of 
arrhythmias in ARVD/C are poorly understood. ARVD2, 
caused by mutations in the ryanodine receptor (RyR2), is 
clinically different from other forms of ARVD/C in that ven-
tricular arrhythmias are stereotypically effort-induced [30]. 
In ARVD2 the leaky ryanodine receptor results in cytosolic 
Ca
2+ overload and, consequently, in delayed afterdepolariza-
tions triggering arrhythmias, and may overlap with CPVT. 
Arrhythmia mechanisms in the structurally normal heart 
  The occurrence of arrhythmias in the absence of any 
structural heart disease is classified as a “primary electrical 
disease”. Ion channelopathies are examples of arrhyth-
mogenic mechanisms generated primarily at the cellular 
level. It is still unclear how arrhythmias are triggered at a 
multicellular level, but the presumption is that delayed repo-
larization increases the spatial voltage gradients sufficiently 
to trigger repetitive excitation of the ventricle. A defect in an 
ion channel alone is not sufficient to induce arrhythmias. 
Extensive phenotypic variability can be seen among family 
members carrying mutations in these channel genes. While 
some family members harboring the mutations suffer from 
sudden cardiac death, other members carrying the same pri-
mary genetic mutations may never develop any arrhythmias. 
The underlying cause for the onset of lethal arrhythmias 
must be therefore multifactorial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Cellular mechanisms of arrhythmias. 
On the cellular level, three distinct entities causing tachyarrhythmias can be distinguished: automaticity, triggered activity and reentry. One 
or a combination of these mechanisms occurs in inherited arrhythmias. AP action potential, HCM hypertrophic cardiomyopathy, DCM di-
lated cardiomyopathy, ARVD/C arrhythmogenic right ventricular dysplasia/cardiomyopathy. 164    Current Genomics, 2008, Vol. 9, No. 3  Wolf and Berul 
Long QT Syndromes 
  The long QT syndrome is characterized by the electro-
cardiographic finding of QT interval prolongation and T 
wave abnormalities in conjunction with a clinical presenta-
tion and/or a family history of syncope, ventricular arrhyth-
mias, and unexpected sudden death. This genetic disorder of 
cardiac electrical repolarization is caused by mutations of 
genes encoding for cardiac potassium and sodium channels, 
usually inherited in an autosomal-dominant fashion. The 
altered ion channel function produces prolongation of the 
action potential and a propensity to torsades de pointes ven-
tricular tachycardia. “Torsades de Pointes” means twisting 
around the point, an allusion to the alternating axis of the 
QRS complex around the isoelectric line of the ECG during 
this arrhythmia. 
  To date, more than ten different types of LQTS have 
been characterized according to their underlying monogenic 
defect (see Table 1 and Fig. 2). 
  LQT1 (42%) and LQT2 (45%) account for about 87% of 
identified mutations, and LQT3 (8%), LQT5 (3%), and 
LQT6 (2%) for the other 13% [37]. Missense mutations in 
the transmembrane and pore domains are the most common 
[37]. Mutant subunits lead to reduction of IKs or IKr by a loss-
of-function mechanism, often with dominant-negative effect 
[38-41].  
  LQT syndrome-associated mutations in SCN5A cause a 
gain-of-function leading to prolonged opening of the sodium 
channel [42, 43].  
  In the heart, reduced IKs or IKr or increased INa leads to 
prolongation of the cardiac action potential, lengthening of 
the QT interval, and increased risk of ventricular arrhythmia 
(see Fig. 2). 
  Genes such as KVLQT1, HERG, SCN5A, KCNE1, and 
KCNE2  have been implicated in the autosomal-dominant 
Romano-Ward syndrome, which is associated with long QT 
syndrome in the absence of other phenotypic abnormalities 
[44]. Mutations in KVLQT1 and KCNE1 also cause the less-
common autosomal recessive Jervell and Lange-Nielsen 
syndrome [45, 46], characterized by congenital bilateral 
deafness associated with marked QT prolongation on the 
electrocardiogram, syncopal attacks due to ventricular ar-
rhythmias and a high risk for sudden death.  
  Recent finding of a mutation in the ANK2 gene encoding 
for ankyrin-B [47] at the LQT4 locus reveals that the pheno-
type of LQTS can also be caused by abnormal proteins other 
that cardiac ion channels. ANK2 mutations modify ankyrin-B 
binding proteins and alter the sodium pump [48], inositol-
1,4,5-triphosphate receptors, and the sodium/calcium ex-
changer function, thereby increasing arrhythmia susceptibil-
ity [47].  
  LQT7, or Andersen syndrome (And1), describes a clini-
cal disorder consisting of potassium-sensitive periodic pa-
ralysis, ventricular arrhythmias, and dysmorphic features 
[49], caused by a missense mutation in the KCNJ2 gene [50]. 
  Timothy's syndrome presents LQT8 and is due to muta- 
tions in the calcium channel Cav1.2 encoded by the gene 
CACNA1c. Since the Calcium channel Cav1.2 is abundant in 
many tissues, patients with Timothy's syndrome have many 
clinical manifestations including congenital heart disease, 
autism, syndactyly and immune deficiency [51]. 
Table 1.  Long QT Syndromes  
More than ten distinct types of congenital long QT (LQT) syndromes due to different gene mutations have been defined to date. Most LQT 
syndromes (LQT1, 2, 5, 6 and 7) are caused by loss-of-function mutations in potassium channels. LQT3 and LQT10 involve mutations in the 
sodium channel. LQT8 is caused by mutations in the L-type calcium channel. LQT4 and LQT9 are caused by structural proteins. 
  Gene Mutations  Affected Protein/Subunit  Ion Channel 
LQT1  KCNQ1 
KVLQT1 
Kv7.1 
IKs 
LQT2  KCNH2 
HERG 
Kv11.1 
IKr 
LQT3  SCN5A  Nav1.5 I Na 
LQT4  Ank2  Ankyrin-B - 
LQT5  KCNE1  MinK I Ks 
LQT6  KCNE2  MiRP1 I Kr 
LQT7  
(Andersen syndrome) 
KCNJ2  Kir2.1 I K1 
LQT8  
(Timothy syndrome) 
CACNA1c  Cav1.21c ICa,L 
LQT9  CAV3  Caveolin-3 - 
LQT10  SCN4B  Nav1.54 INa Molecular Mechanisms of Inherited Arrhythmias  Current Genomics, 2008, Vol. 9, No. 3    165 
  Most recently mutations in the gene CAV3 encoding for 
Caveolin-3, a structural protein, have been described to 
cause LQT9 [52]. Caveolin-3 is the major scaffolding pro-
tein forming specific membrane domains in the heart called 
caveolae and. Caveolin-3 co-localizes and interacts with the 
SCN5A sodium channel, thereby altering ion channel function 
and presumably increasing arrhythmia vulnerability [52]. 
  Last, the Na
+ channel ß4 subunit encoded
 by SCN4B has 
been identified as a novel and rare LQT-susceptibility
 gene 
(LQT10). A missense mutation in SCN4B was found to 
cause a secondary gain of
 function on the Na
+ channel mim-
icking that of classic LQT3-associated mutations
 in SCN5A 
[53]. 
  Understanding the molecular differences between the 
different LQT types is important for risk stratification and 
has clinical implications for the management of LQT pa-
tients. Genetic screening using mutational analysis can im-
prove presymptomatic diagnosis and has recently become 
commercially available. 
  A large phenotype-genotype correlation study showed 
that LQT1 patients are more prone to arrhythmias during 
exercise and swimming, whereas LQT2 and LQT3 patients 
experience more lethal and non-lethal events during rest and 
sleep [1]. The response to medical therapy differs between 
underlying LQT mutation: LQT1 patients seem to respond 
better to beta-blocker therapy than LQT2 and LQT3 patients 
[1, 3].  
  However, clinical heterogeneity among patients with 
long-QT syndrome sharing the same disease-causing muta-
tion challenges their medical management. Some recognized 
modifiers of the clinical phenotype include gender, age, 
drugs, metabolic derangements or hypothermia. Addition-
ally, recent studies provided more evidence for genetic 
modulation altering arrhythmia susceptibility in primary ar-
rhythmia syndromes, such as the presence of compound mu-
tations [54] or the coexistence of modifier alleles or single 
nucleotide polymorphisms [55]. 
  Modifier genes also play a significant role in drug-
induced LQT syndrome. There are differences in responses 
of patients to medication and knowing the gene variants that 
cause differences among patients allow ‘personalized’ drug 
therapy [56]. This is of specific interest regarding drugs that 
are known IKr blockers, such as certain antibiotics, antihista-
mines, antipsychotics and antiarrhythmic agents [57]. 
Brugada Syndrome 
  Brugada and Brugada described an autosomal-dominant 
life-threatening disease occurring in the structurally normal 
heart and characterized by ST segment elevation in the right 
precordial leads (V1 to V3), right bundle branch block, and 
susceptibility to ventricular tachyarrhythmias [58]. The cel-
lular basis for the Brugada syndrome is thought to be due to 
an outward shift in the ionic current active during phase 1 of 
the right ventricular epicardial action potential [59] in which 
Ito is prominent, exaggerating shortening of action potential 
duration in epicardium versus endocardium [60]. 
  Mutations in the SCN5A gene account for less than 25% 
of cases [61]. In contrast to LQT3, these mutations result in a 
loss-of-function of INa [62] (see Fig. 2). 
  Recently, a novel mutation in the glycerol-3-phosphate
 
dehydrogenase 1–like gene (GPD1-L) was identified to 
cause Brugada syndrome. By disrupting trafficking
  of 
SCN5A, GPD1-L mutations decrease SCN5A surface mem-
brane expression and reduces INa [63]. 
Catecholaminergic Polymorphic Ventricular Tachycardia 
  Arrhythmias in catecholaminergic polymorphic ventricu-
lar tachycardia (CPVT) are typically triggered by catechola-
mine surges as occurs with exercise and emotion [64]. An 
alternating QRS axis on a beat-to-beat basis, the so-called 
bidirectional VT, is often the distinguishing pathognomonic 
presentation of CPVT-related arrhythmias [65]. Supraven-
tricular arrhythmias are also frequently observed during ex-
ercise among CPVT patients. 
  Mutations in the ryanodine receptor gene (RyR2) [65, 66] 
and the calsequestrin gene CASQ2  [67], both involved in 
intracellular calcium homeostasis and excitation-contraction 
coupling, are two of the genetic causes of CPVT (see Fig. 2).  
  The underlying pathogenic mechanism of arrhythmias in 
both ryanodine [68] as well as calsequestrin gene mutations 
[69] is a leakiness of the ryanodine receptor causing intracel-
lular Ca
2+ disturbances. Catecholamine surges caused by 
stress or exercise furthermore increase intracellular calcium 
overload and thus trigger afterdepolarizations, resulting in 
polymorphic ventricular tachycardia. 
Idiopathic Ventricular Fibrillation 
  Variable penetrance and distinct modifiers in allelic dis-
orders make disease definitions challenging. If sudden unex-
pected cardiac death occurs and no electrophysiological ab-
normality is recognized, this patient group is categorized as 
having idiopathic ventricular fibrillation. The terminology 
acknowledges the current inability to identify a specific cause 
[70]. Patients who survive an episode of ventricular fibrilla-
tion are at a high risk of recurrence for life-threatening 
events [71].  
  In some patients with idiopathic ventricular fibrillation, 
mutations in the sodium channel encoding gene SCN5A have 
been revealed [72, 73], but a subset of these also present a 
Brugada or LQT like phenotype [74]. 
  Sudden unexplained death syndrome (“SUDS”, or “Lai-
Tai” in Thai) is more prevalent in the Asian as compared to 
the western population. The cause of this disorder is widely 
unknown. Most patients suffering from SUDS show Bru-
gada-like ECG pattern, but mutations in the gene were found 
in a minority of them [75]. Therefore, SCN5A mutations dif-
ferent from previously reported ones or other candidate 
genes might be responsible for SUDS and remain to be in-
vestigated. 
  Recently, genome-wide association studies have found a 
common variant in the nitric oxide synthase 1 adaptor pro-
tein (NOS1AP) to be associated with QT-interval variation 
[76] but increased risk for ventricular fibrillation and sudden 
death could not yet be established [77]. 
FUTURE 
  Understanding of the molecular and ionic mechanisms 
underlying cardiac electrophysiology is essential for the ap-166    Current Genomics, 2008, Vol. 9, No. 3  Wolf and Berul 
preciation of the pathogenesis of cardiac arrhythmias in 
structurally normal and altered hearts. These fundamental 
principles and concepts allow incorporation of genetic fac-
tors in addition to clinical parameters to ultimately improve 
personalized risk assessment and determine optimal therapy 
[14].  
  One area in which technologies are rapidly evolving is 
that of polymorphism identification. These data will be used 
to identify single nucleotide polymorphisms, or groups of 
polymorphisms, that predict particular diseases or individu-
alized responses to drug therapies.  
  Another new therapeutic field is the gene therapy ap-
proach. Gene delivery and cell-based therapies are currently 
being explored for treating the substrate for re-entry after 
myocardial infarction or for replacing electronic pacemakers 
with biological ones [78, 79]. In the experimental setting, 
over-expression of 2-adrenergic receptors [80], use of a 
dominant-negative construct to suppress inward rectifier 
current when expressed together with the wild-type Kir2.1 
[81], and implantation of vectors carrying the pacemaker 
gene HCN2 into atrium [82] or bundle branches [83] have 
been studied. A common problem inherent in these ap-
proaches is the use of viruses to deliver the necessary genes. 
Although the vectors are replication-deficient adenoviruses 
that have little infectious potential, there is concern related to 
the possibility of only a transient improvement in pacemaker 
function as well as potential inflammatory responses [84]. 
  The identification of molecular pathways allows devel-
opment of new therapeutic targets, for both disease palliation 
and cure. Increasing knowledge about disease causing muta-
tions and genotypic-phenotypic correlation opens the doors 
of cardiac electrophysiology to the emerging field of phar-
macogenomics. 
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